microRNA-130b-3p Contained in MSC-Derived EVs Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis.
FOXO3
Keap1
NFE2L2
TXNRD1
extracellular vesicles
lung cancer
mesenchymal stem cells
microRNA-130b-3p
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
20
05
2020
accepted:
16
09
2020
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
This study aimed to explore the molecular mechanism by which mesenchymal stem cells (MSCs) mediate lung cancer progression. Extracellular vesicles (EVs) were isolated from transfected or untransfected MSCs, and were co-cultured with lung cancer cells with/without microRNA-130b-3p (miR-130b-3p) inhibitor, mimic, overexpression plasmids of FOXO3/NFE2L2, or shRNAs. CCK-8 assay, colony formation, transwell assay, and flow cytometry were carried out to determine the biological functioning of lung cancer cells. Furthermore, FOXO3, Keap1, NFE2L2, and TXNRD1 expression was determined by qRT-PCR and western blot analysis. A tumor xenograft mouse model was used to determine role of EVs-miR-130b-3p and its target FOXO3 in lung cancer progression
Identifiants
pubmed: 33575477
doi: 10.1016/j.omto.2020.09.005
pii: S2372-7705(20)30142-X
pmc: PMC7851484
doi:
Types de publication
Journal Article
Langues
eng
Pagination
132-146Informations de copyright
© 2021 The Authors.
Références
Antioxid Redox Signal. 2020 Nov 1;33(13):966-997
pubmed: 31989830
Cancer Res. 2009 May 15;69(10):4134-42
pubmed: 19435900
J Cell Physiol. 2019 Apr;234(4):3394-3409
pubmed: 30362503
Biochem Pharmacol. 2011 Jan 15;81(2):211-21
pubmed: 20920480
J Biol Chem. 2005 Dec 23;280(51):41921-7
pubmed: 16219762
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11
pubmed: 12815096
Mol Pharmacol. 2009 Dec;76(6):1265-78
pubmed: 19786557
Urol Radiol. 1985;7(2):80-4
pubmed: 4012930
RNA. 2014 Sep;20(9):1356-68
pubmed: 25024357
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Theranostics. 2020 Mar 4;10(9):4134-4149
pubmed: 32226544
J Exp Clin Cancer Res. 2016 Jul 01;35(1):105
pubmed: 27364335
Clin Exp Metastasis. 2020 Feb;37(1):115-124
pubmed: 31463796
Cell Physiol Biochem. 2017;42(4):1431-1446
pubmed: 28715819
Hepatology. 2016 Jun;63(6):1914-27
pubmed: 26857210
World Allergy Organ J. 2020 Mar 17;13(3):100110
pubmed: 32206161
Theranostics. 2020 Feb 19;10(8):3767-3778
pubmed: 32206121
Sci Rep. 2019 Aug 27;9(1):12437
pubmed: 31455821
Cell Death Dis. 2019 Dec 16;10(12):953
pubmed: 31844042
J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207
pubmed: 29074454
Int J Mol Sci. 2016 Dec 31;18(1):
pubmed: 28042869
Cancer Lett. 2020 Feb 1;470:29-42
pubmed: 31811910
Cell Death Dis. 2018 Feb 13;9(2):218
pubmed: 29440630
Theranostics. 2020 Apr 6;10(12):5209-5224
pubmed: 32373208
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013711
J Exp Clin Cancer Res. 2020 Jul 13;39(1):134
pubmed: 32660626
Sci Rep. 2017 Jul 28;7(1):6767
pubmed: 28754913
Exp Cell Res. 2016 Jul 15;345(2):190-8
pubmed: 27343631
Stem Cells. 2009 Oct;27(10):2614-23
pubmed: 19650040
Cancer Res. 2013 Sep 1;73(17):5532-43
pubmed: 23824739
Oncotarget. 2017 Sep 18;8(62):104831-104854
pubmed: 29285217
Clin Exp Pharmacol Physiol. 2019 Feb;46(2):137-143
pubmed: 30307642
Sci Rep. 2016 Jul 25;6:30418
pubmed: 27452924
Sci Rep. 2019 May 6;9(1):6956
pubmed: 31061410
Int J Mol Sci. 2016 Feb 06;17(2):172
pubmed: 26861303
Lung Cancer. 2013 Dec;82(3):383-9
pubmed: 24161719
Cell Stem Cell. 2009 Mar 6;4(3):206-16
pubmed: 19265660
J Cell Physiol. 2019 Apr;234(4):3570-3582
pubmed: 30417342
Biochem Biophys Res Commun. 2019 Nov 12;519(3):518-524
pubmed: 31537383
Nat Rev Immunol. 2008 Sep;8(9):726-36
pubmed: 19172693
Life Sci. 2020 Apr 1;246:117366
pubmed: 32001266
Thorac Cancer. 2019 Apr;10(4):642-658
pubmed: 30779316
J Clin Invest. 2017 Jun 1;127(6):2159-2175
pubmed: 28436938
J Biochem. 2020 Jan 1;167(1):101-108
pubmed: 31598681